GlassScriptPhysician profile
Scott W Harberts
NPI 1477551521
$2,791.50
in general payments reported to CMS, 2019-2025
27 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $200 · 2021: $395 · 2022: $416 · 2023: $492 · 2024: $586 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.64 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $554.22 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $347.13 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $202.75 | 2021-2025 | |
| Horizon Therapeutics Plc | $176.45 | 2020-2023 | Krystexxa |
| Vifor Pharma, INC. | $167.85 | 2021-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $160.42 | 2023-2025 | Acthar, Terlivaz |
| Amgen INC. | $150.23 | 2021-2024 | Tavneos, Aranesp, Parsabiv |
| Novartis Pharmaceuticals Corporation | $140.54 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $133.21 | 2021-2023 | Lupkynis |
| Travere Therapeutics, INC. | $127.43 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $99.70 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $91.30 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $74.29 | 2019-2025 | Ultomiris |
| Fresenius USA Marketing, INC. | $58.47 | 2020-2024 | |
| Daiichi Sankyo INC. | $53.78 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $43.98 | 2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $26.37 | 2025 | Jardiance |
| Ardelyx, INC. | $24.85 | 2025 | Ibsrela |
| Novo Nordisk INC | $24.71 | 2024 | Rybelsus, Ozempic |
| Genzyme Corporation | $23.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.06 | 2024 | Jardiance |
| La Jolla Pharmaceutical Company | $17.15 | 2020 | |
| Scpharmaceuticals INC. | $16.38 | 2025 | |
| Amag Pharmaceuticals, INC. | $15.46 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.20 | 2019 | |
| Leadiant Biosciences, INC. | $14.08 | 2024 | Cystaran |
| Pharmacosmos Therapeutics INC. | $13.98 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Harberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.